STOCK TITAN

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

OS Therapies (NYSE: OSTX) announces an exclusive live investor webinar scheduled for October 30, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature presentations from CEO Paul Romness and CBO Gerald Commissiong focusing on the company's novel treatments for Osteosarcoma and solid tumors through OST-HER2 and OST-tADC candidates. The company highlights potential near-term revenue opportunities including out-licensing deals for canine OS ($15M+), human OS ($100M+), OST-tADC SiLinkers™ ($20-80M), and a priority review voucher valued at $100-110M.

OS Therapies (NYSE: OSTX) annuncia un webinar esclusivo dal vivo per gli investitori, programmato per 30 ottobre 2024, alle 16:15 ET. L'evento, ospitato dalle RedChip Companies, presenterà relazioni del CEO Paul Romness e del CBO Gerald Commissiong, concentrandosi sui trattamenti innovativi dell'azienda per l'Osteosarcoma e i tumori solidi tramite i candidati OST-HER2 e OST-tADC. L'azienda evidenzia opportunità di ricavi a breve termine, inclusi accordi di licenza per l'OS canino (oltre $15M), OS umano (oltre $100M), SiLinkers™ OST-tADC (tra $20-80M) e un voucher per revisione prioritaria del valore di $100-110M.

OS Therapies (NYSE: OSTX) anuncia un exclusivo seminario web para inversores programado para el 30 de octubre de 2024, a las 16:15 ET. El evento, organizado por RedChip Companies, contará con presentaciones del CEO Paul Romness y del CBO Gerald Commissiong, enfocándose en los tratamientos novedosos de la empresa para el Osteosarcoma y los tumores sólidos a través de los candidatos OST-HER2 y OST-tADC. La empresa destaca oportunidades de ingresos a corto plazo, incluyendo acuerdos de licencias para OS canino (más de $15M), OS humano (más de $100M), SiLinkers™ OST-tADC (entre $20-80M), y un vale de revisión prioritaria valorado en $100-110M.

OS Therapies (NYSE: OSTX)2024년 10월 30일 오후 4시 15분 ET로 예정된 투자자 전용 라이브 웨비나를 발표했습니다. RedChip Companies가 주최하는 이번 이벤트에서는 CEO Paul Romness와 CBO Gerald Commissiong이 OST-HER2 및 OST-tADC 후보를 통해 골육종 및 고형 종양에 대한 회사의 새로운 치료법에 대해 발표할 예정입니다. 회사는 개 OS($15M 이상), 인간 OS($100M 이상), OST-tADC SiLinkers™($20-80M), 및 $100-110M의 가치가 있는 우선 심사 바우쳐와 같은 단기 수익 기회를 강조하고 있습니다.

OS Therapies (NYSE: OSTX) annonce un webinaire exclusif en direct pour les investisseurs prévu pour le 30 octobre 2024 à 16h15 ET. L'événement, organisé par RedChip Companies, présentera des exposés du PDG Paul Romness et du CBO Gerald Commissiong, axés sur les traitements novateurs de l'entreprise pour l'Ostéosarcome et les tumeurs solides à travers les candidats OST-HER2 et OST-tADC. L'entreprise met en avant des opportunités de revenus à court terme, y compris des accords de licence pour OS canin (plus de 15 millions de dollars), OS humain (plus de 100 millions de dollars), SiLinkers™ OST-tADC (entre 20 et 80 millions de dollars), et un bon de révision prioritaire d'une valeur de 100 à 110 millions de dollars.

OS Therapies (NYSE: OSTX) kündigt ein exklusives Live-Webinar für Investoren an, das für den 30. Oktober 2024 um 16:15 Uhr ET geplant ist. Die Veranstaltung, die von RedChip Companies ausgerichtet wird, umfasst Präsentationen des CEOs Paul Romness und des CBO Gerald Commissiong, die sich auf die neuartigen Behandlungen des Unternehmens für Osteosarkom und solide Tumore durch die Kandidaten OST-HER2 und OST-tADC konzentrieren. Das Unternehmen hebt potenzielle kurzfristige Einnahmechancen hervor, einschließlich Lizenzvereinbarungen für hundliches OS (über 15 Mio. USD), menschliches OS (über 100 Mio. USD), OST-tADC SiLinkers™ (20-80 Mio. USD) und einen Prioritätsprüfungs-Gutschein mit einem Wert von 100-110 Mio. USD.

Positive
  • Multiple potential revenue streams identified with significant values: canine OS ($15M+), human OS ($100M+), SiLinkers™ ($20-80M)
  • Additional revenue potential from priority review voucher valued at $100-110M
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO Paul Romness, and Chief Business Officer Gerald Commissiong. They will share insight into the Company’s pipeline of novel treatments for Osteosarcoma (OS) and other solid tumors. Through innovative product candidates, OST-HER2 and OST-tADC, OS Therapies is not only addressing a significant gap in pediatric and young adult cancer care but also expanding its therapeutic reach to a broader range of solid tumors. OS Therapies’ development programs could significantly alter the trajectory of cancer treatment for a demographic long in need of breakthrough therapies. OS Therapies is on the verge of major clinical milestones and is poised to potentially generate revenues from multiple streams, with out-licensing deals for canine OS ($15M+), human OS ($100M+), and OST-tADC SiLinkers™ ($20-80M) representing near-term revenue potential. A priority review voucher valued at between $100-110M adds another layer of potential revenue.

A live Q&A session with Mr. Romness and Mr. Commissiong will follow the presentation.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_92lvMiAIThmSXrZnfczQbw#/registration

Questions can be pre-submitted to OSTX@redchip.com or online during the live event.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled “Risk Factors” of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the “SEC”) on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Jack Doll

410-297-7793

irpr@ostherapies.com

Source: OS Therapies

FAQ

When is OS Therapies (OSTX) hosting its investor webinar?

OS Therapies (OSTX) is hosting its investor webinar on October 30, 2024, at 4:15 p.m. ET.

What are the potential revenue streams for OS Therapies (OSTX)?

OS Therapies (OSTX) has identified multiple revenue streams including out-licensing deals for canine OS ($15M+), human OS ($100M+), OST-tADC SiLinkers™ ($20-80M), and a priority review voucher valued at $100-110M.

What therapeutic areas does OS Therapies (OSTX) focus on?

OS Therapies (OSTX) focuses on developing treatments for Osteosarcoma (OS) and other solid tumors through their product candidates OST-HER2 and OST-tADC.

OS Therapies Incorporated

NYSE:OSTX

OSTX Rankings

OSTX Latest News

OSTX Stock Data

58.06M
20.89M
24.86%
0.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCKVILLE